Kotak Healthcare Fund Direct Growth
EquitySector - HealthcareVery High Risk
Direct
NAV (25-Jul-24)
Returns (Since Inception)
Fund Overview
Fund Size
₹308 Cr
Expense Ratio
0.72%
ISIN
INF174KA1PZ7
Minimum SIP
₹100
Exit Load
1.00%
Inception Date
11 Dec 2023
About this fund
As of 25-Jul-24, it has a Net Asset Value (NAV) of ₹12.50, Assets Under Management (AUM) of 307.81 Crores, and an expense ratio of 0.72%.
- Kotak Healthcare Fund Direct Growth has given a CAGR return of 24.96% since inception.
- The fund's asset allocation comprises around 98.36% in equities, 0.00% in debts, and 1.64% in cash & cash equivalents.
- You can start investing in Kotak Healthcare Fund Direct Growth with a SIP of ₹100 or a Lumpsum investment of ₹100.
Performance against Category Average
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
+24.96%
— (Cat Avg.)
Portfolio Summaryas of 30th June 2024
| Equity | ₹302.75 Cr | 98.36% |
| Others | ₹5.06 Cr | 1.64% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type  | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹46.23 Cr | 15.02% |
| Cipla Ltd | Equity | ₹27.39 Cr | 8.90% |
| Zydus Lifesciences Ltd | Equity | ₹19.22 Cr | 6.25% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹16.74 Cr | 5.44% |
| Divi's Laboratories Ltd | Equity | ₹16.55 Cr | 5.38% |
| Dr Reddy's Laboratories Ltd | Equity | ₹16.01 Cr | 5.20% |
| Torrent Pharmaceuticals Ltd | Equity | ₹14.51 Cr | 4.72% |
| Alkem Laboratories Ltd | Equity | ₹12.48 Cr | 4.05% |
| Triparty Repo | Cash - Repurchase Agreement | ₹10.2 Cr | 3.31% |
| Mankind Pharma Ltd | Equity | ₹9.58 Cr | 3.11% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹9.23 Cr | 3.00% |
| Innova Captab Ltd | Equity | ₹9.05 Cr | 2.94% |
| Ajanta Pharma Ltd | Equity | ₹9.01 Cr | 2.93% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹8.91 Cr | 2.90% |
| Marksans Pharma Ltd | Equity | ₹8.75 Cr | 2.84% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹8.35 Cr | 2.71% |
| Laurus Labs Ltd | Equity | ₹6.92 Cr | 2.25% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹6.89 Cr | 2.24% |
| Metropolis Healthcare Ltd | Equity | ₹6.77 Cr | 2.20% |
| Fortis Healthcare Ltd | Equity | ₹6.42 Cr | 2.08% |
| Jubilant Pharmova Ltd | Equity | ₹6.29 Cr | 2.04% |
| Biocon Ltd | Equity | ₹6.28 Cr | 2.04% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹6.25 Cr | 2.03% |
| Ami Organics Ltd | Equity | ₹5.82 Cr | 1.89% |
| Net Current Assets/(Liabilities) | Cash | ₹-5.14 Cr | 1.67% |
| Narayana Hrudayalaya Ltd | Equity | ₹4.94 Cr | 1.60% |
| GPT Healthcare Ltd | Equity | ₹4.87 Cr | 1.58% |
| Medi Assist Healthcare Services Ltd | Equity | ₹3.78 Cr | 1.23% |
| Aurobindo Pharma Ltd | Equity | ₹3.14 Cr | 1.02% |
| Alembic Pharmaceuticals Ltd | Equity | ₹2.37 Cr | 0.77% |
Allocation By Market Cap (Equity)
Large Cap Stocks
45.04%
Mid Cap Stocks
30.65%
Small Cap Stocks
22.66%
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹296.93 Cr | 96.47% |
| Basic Materials | ₹5.82 Cr | 1.89% |
Risk & Performance Ratios
Standard Deviation
This fund
--
Cat. avg.
14.65%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.55
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
0.92
Higher the better
Fund Managers
Additional Scheme Detailsas of 30th June 2024
ISIN | INF174KA1PZ7 | Expense Ratio | 0.72% | Exit Load | 1.00% | Fund Size | ₹308 Cr | Age | 11 Dec 2023 | Lumpsum Minimum | ₹100 | Fund Status | Open Ended Investment Company | Benchmark | Nifty Healthcare Index PR INR |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Withdrawal within 1 year
Flat 15% tax on realised gains (STCG - short term capital gains)
Withdrawal after 1 year
10% tax on realised gains above Rs. 1 lakh per financial year (LTCG - long term capital gains)
Note: Mutual funds are subject to capital gains taxation with surcharge and cess, based on prevailing income tax rules and investor income. Taxation applies to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Sector - Healthcare Funds
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y  |
|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹15.00 Cr | 46.7% |
| Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 1.0% | 1.0% | ₹713.42 Cr | 48.3% |
| Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹713.42 Cr | 46.3% |
| Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹29.73 Cr | 45.2% |
| ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹173.47 Cr | 45.0% |
| ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹173.47 Cr | 42.3% |
| Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2312.48 Cr | 45.8% |
| Mirae Asset Healthcare Fund Regular Growth Very High Risk | 2.0% | 1.0% | ₹2312.48 Cr | 43.7% |
| Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹638.88 Cr | 47.4% |
| Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹17.23 Cr | 44.1% |
About the AMC
Total AUM
₹4,47,798 Cr
Address
2nd Floor, 12-BKC, Plot No C-12, Mumbai, 400 051
Other Funds by Kotak Mahindra Mutual Fund
Risk Level
Your principal amount will be at Very High Risk
Unlock Expert Insights!
Related Articles
Still got questions?
We're here to help.
What is the current NAV of Kotak Healthcare Fund Direct Growth?
What is the portfolio composition of Kotak Healthcare Fund Direct Growth?
Who manages the Kotak Healthcare Fund Direct Growth?
- Abhishek Bisen
- Arjun Khanna
- Shibani Kurian
Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377 and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.